Poor
Not Aligned
Patient Risk:
Moderate
Summary
Several drug-interaction statements are unsupported or quantitatively incorrect relative to the provided label excerpts; the only clearly label-supported elements are that atorvastatin is metabolized by CYP3A4 and that strong CYP3A4 inhibitors can increase plasma concentrations (with dose-related caution).
Category Scores
Accurate Statements
Lipitor (atorvastatin) is metabolized by the cytochrome P450 enzyme system in the liver.
Supported by Label 7.1: "LIPITOR is metabolized by CYP3A4." (Provided excerpts do not specify "in the liver"; however CYP metabolism via CYP3A4 is supported.)
Lipitor is primarily metabolized by CYP3A4.
Supported by Label 7.1: "LIPITOR is metabolized by CYP3A4." (Label excerpt does not explicitly use the word "primarily," but states CYP3A4 metabolism.)
Medications that inhibit CYP3A4 can decrease Lipitor breakdown, resulting in higher Lipitor levels and potentially increased risk of side effects.
Supported directionally by Label 7.1: "Concomitant administration with strong CYP3A4 inhibitors can lead to increases in plasma concentrations of atorvastatin."
Ketoconazole inhibits CYP3A4 and increases Lipitor levels.
Not supported by provided label excerpts. (No ketoconazole listing in provided CYP3A4 inhibitor examples.)
Unsupported Statements
Medications that induce CYP3A4 can increase Lipitor breakdown, resulting in lower Lipitor levels and potentially reduced effectiveness.
Provided label excerpts discuss strong CYP3A4 inhibitors increasing plasma concentrations, but do not provide support for CYP3A4 inducers causing reduced atorvastatin levels.
Rifampin induces CYP3A4 and significantly increases Lipitor breakdown.
No rifampin/CYP3A4 inducer effect is provided in the supplied label excerpts.
Rifampin reduced Lipitor levels by 80%.
No quantitative effect for rifampin is provided in the supplied label excerpts.
Carbamazepine induces CYP3A4 and can increase Lipitor breakdown.
No carbamazepine/CYP3A4 inducer effect is provided in the supplied label excerpts.
Carbamazepine reduced Lipitor levels by 50%.
No quantitative effect for carbamazepine is provided in the supplied label excerpts.
Phenytoin induces CYP3A4 and can increase Lipitor breakdown.
No phenytoin/CYP3A4 inducer effect is provided in the supplied label excerpts.
Phenytoin reduced Lipitor levels by 40%.
No quantitative effect for phenytoin is provided in the supplied label excerpts.
Ketoconazole inhibits CYP3A4 and increases Lipitor levels.
No ketoconazole listing or CYP3A4 inhibition effect is included in the supplied label excerpts.
Ketoconazole increased Lipitor levels by 300%.
No quantitative effect for ketoconazole is provided in the supplied label excerpts.
Erythromycin inhibits CYP3A4 and increases Lipitor levels.
Erythromycin is not listed in the provided label excerpts. Provided excerpts list clarithromycin as an example of strong CYP3A4 inhibitor.
Erythromycin increased Lipitor levels by 200%.
No quantitative effect for erythromycin is provided in the supplied label excerpts.
Itraconazole inhibits CYP3A4 and increases Lipitor levels.
Directionally supported only in general terms (strong CYP3A4 inhibitors can increase plasma concentrations). The label excerpt specifically mentions itraconazole as a strong CYP3A4 inhibitor requiring caution when dose exceeds 20 mg, but does not explicitly state magnitude for level increases.
Itraconazole increased Lipitor levels by 150%.
No quantitative effect for itraconazole is provided in the supplied label excerpts.
Lipitor breakdown can be affected by age, with older adults experiencing slower breakdown rates.
Provided label excerpt for geriatric use states increased risk of myopathy "since advanced age (≥65 years) is a predisposing factor," but does not state slower breakdown rates.
Lipitor breakdown can be affected by liver function, with individuals with liver disease experiencing slower breakdown rates.
Provided label excerpts specify contraindication in active liver disease and recommendations for liver function testing, but do not state that liver disease slows atorvastatin breakdown.
Genetic variations in the CYP3A4 gene can affect Lipitor breakdown rates.
No pharmacogenetic/CYP3A4 genetic variation statements are included in the supplied label excerpts.
Contradictions
Low
AI Statement
Medications that induce CYP3A4 can increase Lipitor breakdown, resulting in lower Lipitor levels and potentially reduced effectiveness.
Label Reference
Label does not discuss CYP3A4 inducers or lower atorvastatin levels in the provided excerpts; this is unsupported rather than directly contradicting provided text.
Important Omissions
For strong CYP3A4 inhibitors, the label excerpt provides caution that when LIPITOR dose exceeds 20 mg, "appropriate clinical assessment is recommended" and that risk of myopathy increases with strong CYP3A4 inhibitors; the AI claims omit dose-exceedance caution details tied to itraconazole/clarithromycin category and do not reference the myopathy/rhabdomyolysis risk linkage.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported quantitative interaction effects (e.g., rifampin/carba/phenytoin and multiple-fold increases) could mislead on exposure changes; partial alignment with general CYP3A4 inhibitor concept but missing label-supported risk/dose-caution context.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple claims (especially inducer effects and specific numeric magnitude changes) are not supported by the provided label excerpts; several interacting drugs are not listed in the supplied prescribing information.
Suggested Improvement
Restrict interaction statements to what the label excerpts support: atorvastatin metabolized by CYP3A4 and that strong CYP3A4 inhibitors (examples: clarithromycin, itraconazole; with dose caution >20 mg) can increase plasma concentrations and increase myopathy risk. Remove/replace quantitative percentage changes and inducer claims not present in the supplied label text.